Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease

Anders Løkke, Luca Castello, Pedro Pinheiro Martins, Stéphane Soulard*, Ole Hilberg

*Kontaktforfatter

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

2 Downloads (Pure)

Abstract

Introduction: Progression of fibrosis in interstitial lung diseases (ILD) has been associated with poor prognosis, lower quality of life for patients and caregivers, and higher healthcare costs. This study estimated the burden of disease and productivity loss of progressively fibrosing ILD, focusing on progressive pulmonary fibrosis other than idiopathic pulmonary fibrosis (non-IPF PPF) and systemic sclerosis-associated ILD (SSc-ILD) in the European Economic Area (EEA). Methods: An economic model was built to estimate the clinical burden of SSc-ILD and non-IPF PPF. The model was based on published data on disease prevalence and disease burden (in terms of comorbidities, exacerbations, and deaths) as well as on productivity loss (in terms of sick days, early retirement, permanent disability, and job loss). Aggregate income loss was obtained by multiplying productivity loss by the median daily income in each country/area of investigation. A sensitivity analysis was performed to test the impact of the variability of the model assumptions. Results: In the whole EEA, a total of 86,794 and 13,221 individuals were estimated to be affected by non-IPF PPF and SSc-ILD, respectively. Estimated annual sick days associated with the diseases were 3,952,604 and 672,172, early retirements were 23,174 and 5341, permanently disabled patients were 41,748 and 4037, and job losses were 19,789 and 2617 for non-IPF PPF and SSc-ILD, respectively. Annual exacerbations were estimated to be 22,401–31,181 and 1259–1753, while deaths were 5791–6171 and 572–638 in non-IPF PPF and SSc-ILD, respectively. The estimated annual aggregate income loss in EEA, accounting for losses due to annual sick days, early retirements, and permanently disabled patients, was €1433 million and €220 million in non-IPF PPF and SSc-ILD, respectively. The productivity loss due to job losses was €194 million and €26 million in non-IPF PPF and SSc-ILD, respectively. The main driver of aggregate income loss variability was the prevalence. Conclusion: The impact of non-IPF PPF and SSc-ILD on society is definitely non-negligible. Actions to reduce the burden on our societies are highly needed.

OriginalsprogEngelsk
TidsskriftAdvances in Therapy
Vol/bind40
Udgave nummer12
Sider (fra-til)5502-5518
ISSN0741-238X
DOI
StatusUdgivet - 14. okt. 2023

Bibliografisk note

Funding Information:
We acknowledge Laura Fascio Pecetto from SEEd Medical Publishers, who provided medical writing, publishing support, and journal styling services. These services were funded by Boehringer Ingelheim. All authors whose names appear on the submission have: (1) Made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work. (2) Drafted the work or revised it critically for important intellectual content. (3) Approved the version to be published; and (4) Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy of integrity of any part of the work are appropriately investigated and resolved.

Funding Information:
This study was funded by Boehringer Ingelheim bv. (Amsterdam, the Netherlands), which also funded medical writing, publishing support, and journal styling services. The authors did not receive payment related to the development of the manuscript. The study sponsor is also funding the journal’s Rapid Service and Open Access Fees.

Publisher Copyright:
© 2023, The Author(s).

Fingeraftryk

Dyk ned i forskningsemnerne om 'Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease'. Sammen danner de et unikt fingeraftryk.

Citationsformater